Australia - engleză - Department of Health (Therapeutic Goods Administration)

care pharmaceuticals pty ltd - citric acid monohydrate, quantity: 4.8 mg/ml; glucose monohydrate, quantity: 16 mg/ml; sodium chloride, quantity: 2.5 mg/ml; potassium citrate, quantity: 2.2 mg/ml (equivalent: potassium, qty 800 microgram/ml) - oral liquid - excipient ingredients: carmellose sodium; potassium sorbate; sodium benzoate; sucralose; purified water; flavour - decrease/reduce/relieve symptoms of dehydration ; maintain/support body electrolyte balance ; helps restore body electrolyte balance ; helps decrease/reduce/relieve symptoms of traveller's diarrhoea ; helps decrease/reduce/relieve symptoms of occasional hangovers

Singapore - engleză - HSA (Health Sciences Authority)

icm pharma pte. ltd. - citric acid; potassium citrate - solution - 5% w/v - citric acid 5% w/v; potassium citrate 30% w/v

Regatul Unit - engleză - VMD (Veterinary Medicines Directorate)

eli lilly & company ltd - citric acid anhydrous , glucose monohydrate, glycine, potassium citrate monohydrate, potassium dihydrogen phosphate, sodium chloride -

Regatul Unit - engleză - VMD (Veterinary Medicines Directorate)

eli lilly & company ltd - citric acid anhydrous , glucose monohydrate, glycine, potassium citrate monohydrate, sodium chloride -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

care pharmaceuticals pty ltd - citric acid monohydrate, quantity: 4.8 mg/ml; glucose monohydrate, quantity: 16 mg/ml; sodium chloride, quantity: 2.5 mg/ml; potassium citrate, quantity: 2.2 mg/ml (equivalent: potassium, qty 800 microgram/ml) - oral liquid - excipient ingredients: sodium benzoate; potassium sorbate; carmellose sodium; purified water; sucralose; flavour; colour - decrease/reduce/relieve symptoms of dehydration ; maintain/support body electrolyte balance ; helps restore body electrolyte balance ; helps decrease/reduce/relieve symptoms of traveller's diarrhoea ; helps decrease/reduce/relieve symptoms of occasional hangovers

Australia - engleză - Department of Health (Therapeutic Goods Administration)

care pharmaceuticals pty ltd - potassium citrate, quantity: 2.2 mg/ml (equivalent: potassium, qty 800 microgram/ml); citric acid monohydrate, quantity: 4.8 mg/ml; glucose monohydrate, quantity: 16 mg/ml; sodium chloride, quantity: 2.5 mg/ml - oral liquid - excipient ingredients: purified water; carmellose sodium; potassium sorbate; sucralose; sodium benzoate; flavour; colour - decrease/reduce/relieve symptoms of dehydration ; maintain/support body electrolyte balance ; helps restore body electrolyte balance ; helps decrease/reduce/relieve symptoms of traveller's diarrhoea ; helps decrease/reduce/relieve symptoms of occasional hangovers

Australia - engleză - Department of Health (Therapeutic Goods Administration)

care pharmaceuticals pty ltd - potassium citrate, quantity: 2.2 mg/ml (equivalent: potassium, qty 800 microgram/ml); citric acid monohydrate, quantity: 4.8 mg/ml; sodium chloride, quantity: 2.5 mg/ml; glucose monohydrate, quantity: 16 mg/ml - oral liquid - excipient ingredients: purified water; potassium sorbate; sucralose; sodium benzoate; flavour; colour - decrease/reduce/relieve symptoms of dehydration ; maintain/support body electrolyte balance ; helps restore body electrolyte balance ; helps decrease/reduce/relieve symptoms of traveller's diarrhoea ; helps decrease/reduce/relieve symptoms of occasional hangovers

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bryant ranch prepack - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)]. potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. potassium citrate is contraindicated: - in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those sufferi

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bryant ranch prepack - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)] . potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)] . potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)] . potassium citrate extended-release tablets are contraindicated: • in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bryant ranch prepack - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)] . potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. potassium citrate extended-release tablets are contraindicated: - in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal t